Feagan 2013.

Study characteristics
Methods	Randomized, double‐blind, placebo‐controlled, multicenter, phase 3 study
Participants	Adults (18 years or older) with a documented diagnosis of mild‐to‐moderate UC, defined by a modified UC‐DAI (N = 281)
Interventions	Asacol 4.8 g/day (n = 140) or placebo (n = 141)
Outcomes	Primary outcome: proportion of participants in clinical remission, defined as a score of 0 for stool frequency and rectal bleeding, and absence of fecal urgency at week 6 Secondary outcomes: clinical remission at weeks 6 and 10, endoscopic remission (defined as a sigmoidoscopic score of < 1) at week 6, endoscopic remission at week 10, improvement (defined as a decrease of at least 3 points from baseline in the modified UC‐DAI score) at week 6, improvement at week 10, mean changes in the modified UC‐DAI and UCCS from baseline to week 10, and adverse events
Notes	Study was funded by Tillotts Pharma, AG. Author conflicts of interest are reported in the manuscript
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Generated in permutated blocks by computer
Allocation concealment (selection bias)	Low risk	An interactive voice/web response system managed the randomization procedure and dispensed the study drug
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants and central readers were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants involved in the trial were accounted for with reasons
Selective reporting (reporting bias)	Low risk	Expected outcomes were reported in the published study
Other bias	Low risk	The study appears to be free of other sources biases